Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 9/20 | 0.68 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.68 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.68 |
| ▸ | MRGPRX2 | Q96LB1 | 4/20 | 0.68 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.68 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.68 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.68 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.56 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.56 |
| ▸ | ARRB1 | P49407 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11450667 | 0.89 | OPRD1 (0.69) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL15738051 | 0.89 | OPRM1 (0.69) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL1662579 | 0.89 | OPRM1 (0.69) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL15734327 | 0.89 | OPRD1 (0.68) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL28136408 | 0.89 | OPRD1 (0.68) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL3982466 | 0.88 | OPRD1 (0.65) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL27672335 | 0.88 | OPRM1 (0.67) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL30362250 | 0.87 | OPRD1 (0.67) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL2856631 | 0.87 | OPRM1 (0.66) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL29360168 | 0.87 | OPRM1 (0.66) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137670-A1 | SUSTAINED RELEASE DRUG DELIVERY SYSTEMS AND RELATED METHODS | DURECT CORP (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260060822-A1 | BIOENGINEERED SCAFFOLDS FOR VASCULAR GRAFTS AND METHODS OF USE THEREOF | UNIV WAKE FOREST HEALTH SCIENCES (US) | 2026-03-05 | — | — | US | disclosed |
| US-12527770-B2 | Methods of managing pain using dexmedetomidine transdermal delivery devices | TEIKOKU PHARMA USA, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250366978-A1 | DEVICES AND METHODS OF MAKING AND USE THEREOF | METHODIST HOSPITAL (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250366979-A1 | DEVICES AND METHODS OF MAKING AND USE THEREOF | METHODIST HOSPITAL (US) | 2025-12-04 | — | — | US | disclosed |
| US-12433877-B2 | Sustained release drug delivery systems and related methods | DURECT CORPORATION (US) | 2025-10-07 | — | — | US | disclosed |
| US-20250251323-A1 | COLLECTION PROBE AND METHODS OF USE THEREOF | BAYLOR COLLEGE OF MEDICINE | 2025-08-07 | — | — | US | disclosed |
| WO-2025128946-A1 | DEVICES AND METHODS OF MAKING AND USE THEREOF | THE METHODIST HOSPITAL (US) | 2025-06-19 | — | — | WO | disclosed |
| EP-4536138-A1 | DEVICES AND METHODS OF MAKING AND USE THEREOF | The Methodist Hospital (US) | 2025-04-16 | — | — | EP | disclosed |
| EP-4536139-A1 | DEVICES AND METHODS OF MAKING AND USE THEREOF | The Methodist Hospital (US) | 2025-04-16 | — | — | EP | disclosed |
| CN-110022865-A | METHODS OF MANAGING PAIN USING DEXMEDETOMIDINE TRANSDERMAL DELIVERY DEVICES | 帝国制药美国公司 | 2019-07-16 | — | — | CN | disclosed |
| US-20190175519-A1 | Naloxone Transdermal Delivery Devices and Methods for Using the Same | TEIKOKU PHARMA USA, INC. | 2019-06-13 | — | — | US | disclosed |
| WO-2018081812-A2 | METHODS OF MANAGING PAIN USING DEXMEDETOMIDINE TRANSDERMAL DELIVERY DEVICES | TEIKOKU PHARMA USA, INC. (US) | 2018-05-03 | — | — | WO | disclosed |
| US-20180117012-A1 | Methods of Managing Pain Using Dexmedetomidine Transdermal Delivery Devices | TEIKOKU PHARMA USA, INC. | 2018-05-03 | — | — | US | disclosed |
| EP-3054934-A1 | METHODS AND COMPOSITIONS FOR TREATING WITHDRAWAL SYNDROMES USING NON-SEDATIVE DEXMEDETOMIDINE TRANSDERMAL COMPOSITIONS | Teikoku Pharma USA, Inc. (US) | 2016-08-17 | — | — | EP | disclosed |
| CN-105682650-A | Methods and compositions for treating withdrawal syndrome using non-sedating dexmedetomidine transdermal compositions | 帝国制药美国公司 | 2016-06-15 | — | — | CN | disclosed |
| CN-104955508-A | Methods and devices for compound delivery | NICOTINE TECHNOLOGY INC E | 2015-09-30 | — | — | CN | disclosed |
| WO-2015054063-A1 | METHODS AND COMPOSITIONS FOR TREATING WITHDRAWAL SYNDROMES USING NON-SEDATIVE DEXMEDETOMIDINE TRANSDERMAL COMPOSITIONS | TEIKOKU PHARMA USA, INC. (US) | 2015-04-16 | — | — | WO | disclosed |
| US-20150098983-A1 | Methods and Compositions for Treating Withdrawal Syndromes Using Non-Sedative Dexmedetomidine Transdermal Compositions | TEIKOKU PHARMA USA, INC. | 2015-04-09 | — | — | US | disclosed |
| CN-204147375-U | Be designed for the aerosol generation equipment producing condensation aerosol | NICOTINE TECHNOLOGY INC E | 2015-02-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180117012-A1 | Methods of Managing Pain Using Dexmedetomidine Transdermal Delivery Devices | OPRL1, OPRK1, AVPR2 | OPRD1 5/4885OPRM1 6/4885OPRK1 2/4885 |
| US-20190175519-A1 | Naloxone Transdermal Delivery Devices and Methods for Using the Same | OPRL1, OPRK1, OPRM1 | OPRD1 5/4885OPRM1 3/4885OPRK1 2/4885 |
| US-20260137670-A1 | SUSTAINED RELEASE DRUG DELIVERY SYSTEMS AND RELATED METHODS | SLC10A2, OPRK1, HBB | OPRD1 63/4885OPRM1 5/4885OPRK1 2/4885 |
| US-20260060822-A1 | BIOENGINEERED SCAFFOLDS FOR VASCULAR GRAFTS AND METHODS OF USE THEREOF | PFKP, PBK, MYLK | OPRD1 4518/4885OPRM1 4810/4885OPRK1 2862/4885 |
| US-12527770-B2 | Methods of managing pain using dexmedetomidine transdermal delivery devices | OPRD1, OPRK1, OPRM1 | OPRD1 1/4885OPRM1 3/4885OPRK1 2/4885 |
| US-20150098983-A1 | Methods and Compositions for Treating Withdrawal Syndromes Using Non-Sedative Dexmedetomidine Transdermal Compositions | CRH, OPRD1, ADRA2C | OPRD1 2/4885OPRM1 44/4885OPRK1 4/4885 |
| US-12433877-B2 | Sustained release drug delivery systems and related methods | OPRM1, OPRK1, SLC7A5 | OPRD1 17/4885OPRM1 1/4885OPRK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.